1-10 of 10
Tomas Kozak, MD, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Early Progression after R-CHOP in Follicular Lymphoma: Key Role for the Maintenance Therapy

Free
Vit K Prochazka, MD PhD Assoc Prof, Tomas Papajik, MD prof., Andrea Janikova, MD PhD, Assoc Prof, David Belada, Tomas Kozak, MD, PhD, Prof., David Salek, MD PhD, Alice Sykorova, MD PhD, Heidi Mocikova, MD, PhD, Vit Campr, MD PhD, Jitka Dlouha, Tomas Fuerst, MSc, PhD, Marek Trneny
Journal: Blood
Blood (2016) 128 (22): 1779.
https://doi.org/10.1182/blood.V128.22.1779.1779
Published: 2016
Journal Articles

Outcome of Patients with Hodgkin Lymphoma transformed from Chronic Lymphocytic Leukemia

Free
Heidi Mocikova, MD, PhD, Jana Markova, MD, Lubica Gaherova, MD, Lukas Smolej, MD, PhD, Assoc.Prof., Martin Simkovic, MD, Tomas Kozak, MD, PhD, Prof.
Journal: Blood
Blood (2015) 126 (23): 5298.
https://doi.org/10.1182/blood.V126.23.5298.5298
Published: 2015
Journal Articles

Defining Criteria for Diagnosis of Occult Lymphomatous Involvement in Cerebrospinal Fluid

Free
Heidi Mocikova, MD, PhD, Magdalena Klanova, MD, Martin Spacek, MD, PhD, Robert Pytlik, MD, PhD, Tomas Kozak, MD, PhD, Prof., Marek Trneny, MD, PhD, Prof., Vit Pospisil, PhD
Journal: Blood
Blood (2014) 124 (21): 5412.
https://doi.org/10.1182/blood.V124.21.5412.5412
Published: 2014
Journal Articles

MicroRNA Analysis in the Cerebrospinal Fluid and Blood Serum of Lymphoma Patients At Diagnosis and in Response to Therapy,

Free
Vit Pospisil, Heidi Mocikova, MD, PhD, Milada Jankovska, MD, Jana Markova, MD, Lubica Gaherova, MD, Tomas Kozak, MD, PhD, Tomas Stopka, MD, PhD
Journal: Blood
Blood (2011) 118 (21): 3663.
https://doi.org/10.1182/blood.V118.21.3663.3663
Published: 2011
Journal Articles

Immunochemotherapy with Low-Dose Subcutaneous Alemtuzumab (A) Plus Oral Fludarabine and Cyclophosphamide (FC) Is Safe and Induces More and Deeper Complete Remissions in Untreated Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) Than Chemotherapy with FC Alone. An Early Analysis of the Randomized Phase-III HOVON68 CLL Trial

Free
Christian H Geisler, MD, PhD, Mars MB van 't Veer, MD, PhD, Wim van Putten, MSc, Jesper Jurlander, MD.PHD, Jan Walewski, MD, PhD, Geir Tjonnfjord, MD, PHD, Maija Itälä-Remes, MD, PHD, Eva Kimby, M.D., Ph.D., Tomas Kozak, MD, PhD, Aaron Polliack, MD, Shulamiet Wittebol, MD, Fokje Spoelstra, PhD, Marinus H.J. Van Oers, MD, PhD
Journal: Blood
Blood (2011) 118 (21): 290.
https://doi.org/10.1182/blood.V118.21.290.290
Published: 2011
Journal Articles

Identification of Novel Molecular Markers for the Follow-up of Minimal Residual Disease in Hematooncological Disorders

Free
David Warren Hardekopf, Tereza Jancuskova, Marie Jarosova, Lucie Krutilkova, Radek Plachy, Lenka Zejskova, Radek Cmejla, PhD, Jan Vydra, Tomas Kozak, MD, PhD, Michal Karas, Vladimir Koza, MD, Alzbeta Zavrelova, MD, Pavel Zak, MD, PhD, Lukas Smolej, M.D., Ph.D., Sona Pekova
Journal: Blood
Blood (2011) 118 (21): 4905.
https://doi.org/10.1182/blood.V118.21.4905.4905
Published: 2011
Journal Articles

Ofatumumab (HuMax-CD20), a Novel CD20 Monoclonal Antibody, Is An Active Treatment for Patients with CLL Refractory to Both Fludarabine and Alemtuzumab or Bulky Fludarabine-Refractory Disease: Results from the Planned Interim Analysis of An International Pivotal Trial

Free
Anders Osterborg, MD, PhD, Thomas J. Kipps, MD, PhD, Jiri Mayer, MD, Stephan Stilgenbauer, Dr.med, Catherine D Williams, MBBS, MRCP, FRCPath, Andrzej Hellmen, MD, PhD, Tadeusz Robak, MD, PhD, Richard R Furman, MD, Peter Hillmen, MBChB, PhD, Marek Trneny, MD, PhD, Martin J.S. Dyer, MA, DPhil, FRCP, Swaminathan Padmanabhan, MD, MBBS, Tomas Kozak, MD, PhD, Geoffrey Chan, MD, Randy L Davis, DrPH, Nedjad Losic, MSc, Charlotte A. Russell, MD, DMSC, Magdalena Piotrowska, MD, Joris Wilms, MSc., Pharm, William G. Wierda, MD, PhD
Journal: Blood
Blood (2008) 112 (11): 328.
https://doi.org/10.1182/blood.V112.11.328.328
Published: 2008
Journal Articles

Molecular Variability of FLT3/ITD Mutants and Their Impact on the Differentiation Program of 32D Cells: Implications for the Biological Properties of AML Blasts

Free
Sona Pekova, M.D., PhD., Michal Dvorak, PhD., Robert Ivanek, Sabrina Rueggeberg, Stefan Leicht, Tomas Kozak, MD, PhD, Jiri Vrba, MD., Jiri Schwarz, MD., PHD., Petr Cetkovsky, MD., PHD., Miroslav Prucha, MD., PHD., Ondrej Hrusak
Journal: Blood
Blood (2008) 112 (11): 4480.
https://doi.org/10.1182/blood.V112.11.4480.4480
Published: 2008
Journal Articles

Standard and Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantations (HSCT) from Related and Unrelated Donors for Chronic Lymphocytic Leukemia (CLL). a Long-Term Follow-up (10 years) Study from the EBMT Registry. (CLL Sub-Committee on Behalf of EBMT CLWP)

Free
Mauricette Michallet, MD, PhD, Quoc Hung Le, MD, Peter Dreger, Mohamad Sobh, PhD, Dietger Niederwieser, MD, Vladimir Koza, MD, Tapani Ruutu, Nigel H. Russell, MD, Leo Verdonck, Donald Milligan, MD, MBChB, Nathalie Dhedin, Tomas Kozak, MD, PhD, Marc Boogaerts, MD, PhD, Juergen Finke, Nathalie Tedone, Anja Van Biezen, Ronald Brand, Theo de Witte on behalfhe European Group for Blood Marrow Transplantation
Journal: Blood
Blood (2008) 112 (11): 566.
https://doi.org/10.1182/blood.V112.11.566.566
Published: 2008
Journal Articles

Delta Ex6, the Novel Transactivation-Defective Splicing Variant of p53 Gene, Is Differentially Expressed in Patients with Chronic Lymphocytic Leukemia and Confers Accented Proliferative Phenotype in Vitro

Free
Sona Pekova, M.D., PhD., Radek Cmejla, PhD, Tomas Kozak, MD, PhD, Lukas Smolej, MD, PhD, Martin Spacek, MD., Miroslav Prucha, MD., PhD., Ondrej Hrusak
Journal: Blood
Blood (2008) 112 (11): 3795.
https://doi.org/10.1182/blood.V112.11.3795.3795
Published: 2008